Glucagon-like peptide 1 receptor agonist therapy is associated with lower risks of several cancers (e.g., prostate, lung, and colon cancer) and a higher risk of thyroid cancer [11]. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.